NASDAQ
22.09.25 | 21:59
1,600 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Tela Bio reiterates $85M-$88M 2025 revenue target as international expansion accelerates | 1 | Seeking Alpha | ||
| 11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.08. | TELA Bio GAAP EPS of -$0.22, revenue of $20.2M | 4 | Seeking Alpha | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | TELA Bio, Inc.: TELA Bio Reports Second Quarter 2025 Financial Results | 124 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 08.08. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 136 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 21.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 06.06. | TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 160 | GlobeNewswire (Europe) | MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 03.06. | TELA Bio, Inc.: TELA Bio Announces European Commercial Launch of OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair | 119 | GlobeNewswire (Europe) | MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 02.06. | TELA Bio ernennt Jeffrey Blizard zum neuen Präsidenten | 2 | Investing.com Deutsch | ||
| 02.06. | TELA Bio, Inc.: TELA Bio Appoints Jeffrey Blizard as President | 154 | GlobeNewswire (Europe) | MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 30.05. | TELA Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 20.05. | Piper Sandler maintains TELA Bio stock at Neutral with $2 target | 2 | Investing.com | ||
| 09.05. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 123 | GlobeNewswire (Europe) | MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 09.05. | TELA Bio GAAP EPS of -$0.25 misses by $0.05, revenue of $18.5M beats by $1.15M | 2 | Seeking Alpha | ||
| 08.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 09.04. | Canaccord maintains TELA Bio stock with $7 target post-challenges | 1 | Investing.com | ||
| 31.03. | TELA Bio introduces larger sizes for soft tissue reconstruction | 1 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 22,725 | +6,19 % | Moderna, Inc.: Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories | CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,815 | +0,06 % | BMO upgrades Sarepta on Elevidys uptake, pipeline prospects | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,080 | -0,83 % | PacBio enters high-throughput carrier screening market with expanded test suite | ||
| MYRIAD GENETICS | 6,800 | +2,26 % | Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now? | ||
| PHIO PHARMACEUTICALS | 2,235 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Future Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,725 | -0,98 % | Cantor Fitzgerald initiates CytomX Therapeutics stock coverage with Overweight rating | ||
| VIR BIOTECHNOLOGY | 5,270 | 0,00 % | H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock | ||
| RAPT THERAPEUTICS | 16,700 | -1,76 % | XFRA 0RA0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient | First patient in Cohort B achieved CR after 2nd dose of TCB008
EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,100 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| 89BIO | 14,870 | +0,07 % | Roche kauft amerikanische 89bio für bis zu 3,5 Milliarden Dollar | BASEL (dpa-AFX) - Roche übernimmt für bis zu 3,5 Milliarden US-Dollar die amerikanische 89bio. Das Biopharma-Unternehmen leistet laut Roche Pionierarbeit bei der Entwicklung innovativer Therapien zur... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,440 | +2,44 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| MBX BIOSCIENCES | 20,000 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension | Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in... ► Artikel lesen | |
| NUVALENT | 78,90 | 0,00 % | Nuvalent schließt FDA-Zulassungsantrag für Lungenkrebsmedikament Zidesamtinib ab | ||
| QIAGEN | 38,980 | -0,06 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen |
TELA BIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.